AI Terminal
POLAREAN IMAGING PLC
Declaration of Voting Results & Voting Rights Announcements • Jul 13, 2021
7850_dva_2021-07-13_bf2de86c-dcf2-413b-9ba1-3594409d3bc3.html
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1151F
Polarean Imaging PLC
13 July 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Result of AGM
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:
| Resolution | For | Against |
| Resolution 1 | 85,455,493 | 4,503,288 |
| Resolution 2 | 85,433,826 | 4,513,963 |
| Resolution 3 | 92,932,443 | 10,780 |
| Resolution 4 | 92,939,943 | 10,780 |
| Resolution 5 | 92,215,560 | 735,163 |
| Resolution 6 | 92,880,692 | 63,039 |
| Resolution 7 | 84,558,967 | 5,391,222 |
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
| Jonathan Allis, Chairman | ||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||
| Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) | ||||
| Nick Adams / Fred Walsh (Corporate Broking) | ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |||
| Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 | |||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSFFFDDEFSEEW